‘Opioids’ Is Missing From The US FDA’s Overdose Prevention Framework Title On Purpose
Executive Summary
Unlike prior plans, the FDA’s new substance abuse framework is intended to deal with stimulant and benzodiazepine use disorders, in addition to opioid abuse.
You may also be interested in...
US FDA Looking For Senior Leader In New Drugs Office To Oversee Substance Use Disorder Issues
The deputy Office of New Drugs director will have decision-making authority and help shape policy for substance use efforts.
Supplemental Filings: Ycanth Approved For Molluscum; CDER Counter-Terrorism Head Retires; 5 Benzodiazepines Added To Schedule I
The fourth review cycle is the charm for Verrica's cantharidin topical solution; Rosemary Roberts, head of CDER's Counter-Terrorism and Emergency Coordination Staff, retires after 35 years at the FDA; DEA deems five designer benzodiazepines with no currently accepted medical use in the US as Schedule I controlled substances.
New Opioid Labeling Further Constrains Use, Urges Prescribing Only By Docs ‘Knowledgeable’ About Risks
US FDA’s mandated labeling changes come after the agency required manufacturers to provide mail-back envelopes for opioid disposal.